Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Hypercholesterolaemia; Intracranial-Arteriosclerosis; Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR Outcomes; CVOT
  • Sponsors Esperion Therapeutics

Most Recent Events

  • 30 Mar 2026 According to an Esperion Therapeutics media release, data were presented as moderated poster presentations at the American College of Cardiology's Annual Scientific Session (ACC.26) 2026.
  • 30 Mar 2026 Results published in the Media Release
  • 17 Mar 2026 According to an Esperion Therapeutics media release, data from this study will be presented at the upcoming American College of Cardiology's 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top